These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29694823)

  • 41. [Interferon for adjuvant therapy in melanoma; although approved, not indicated].
    Groenewegen G; Osanto S; van der Rhee HJ; Punt CJ
    Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2160-2. PubMed ID: 11086492
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical prognostic factors in adjuvant melanoma trial.
    Nathanson L
    J Clin Oncol; 1996 Jun; 14(6):1967-8. PubMed ID: 8656271
    [No Abstract]   [Full Text] [Related]  

  • 43. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
    Kimyai-Asadi A; Usman A
    J Am Acad Dermatol; 2000 Oct; 43(4):708-11. PubMed ID: 11004636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
    Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
    J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Who benefits most from adjuvant interferon treatment for melanoma?
    Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
    Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance.
    Doveil GC; Fierro MT; Novelli M; Appino A; Bertero M; Quaglino P; Bernengo MG
    Dermatology; 1995; 191(3):234-9. PubMed ID: 8534942
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant Melanoma Therapy - Head-Spinning Progress.
    Schuchter LM
    N Engl J Med; 2017 Nov; 377(19):1888-1890. PubMed ID: 29117487
    [No Abstract]   [Full Text] [Related]  

  • 48. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recurrent laryngeal metastasis of a malignant melanoma: surgical therapy with the first application of mitomycin C.
    Echternach M; Arndt S; Mattern D; Maier W; Richter B
    J Otolaryngol Head Neck Surg; 2009 Feb; 38(1):E19-22. PubMed ID: 19344599
    [No Abstract]   [Full Text] [Related]  

  • 50. How does interferon work? Does it even matter?
    Sondak VK
    Cancer; 2002 Sep; 95(5):947-9. PubMed ID: 12209676
    [No Abstract]   [Full Text] [Related]  

  • 51. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
    J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Recombinant interferon alfa-2b in the treatment of patients with skin melanoma].
    Korovin SI
    Lik Sprava; 1998; (2):139-41. PubMed ID: 9670687
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Current therapy of carcinoma of the skin].
    Dummer R; Goldinger SM; Sailer E; French LE
    Ther Umsch; 2010 Sep; 67(9):447-52. PubMed ID: 20806173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Urticaria, angioedema and dyspnoea in adjuvant therapy of melanoma with interferon alpha-2b.
    Helbig D; Simon JC; Treudler R
    Acta Derm Venereol; 2010 May; 90(3):308-9. PubMed ID: 20526557
    [No Abstract]   [Full Text] [Related]  

  • 55. [Adjuvant therapy with recombinant interferon alfa-2a in metastasized malignant melanoma].
    Elsässer-Beile U; Garbe C; Stadler R; Drews H; Schöpf E
    Hautarzt; 1989 May; 40(5):266-70. PubMed ID: 2737901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [After removal of a malignant melanoma. Enhancing the immune system!].
    MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
    [No Abstract]   [Full Text] [Related]  

  • 57. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
    Eggermont AM; Bouwhuis MG; Kruit WH; Testori A; ten Hagen T; Yver A; Xu C
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):671-7. PubMed ID: 19621225
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Ocular complications of adjuvant interferon therapy for malignant melanoma: a review].
    Ockenfels M; Lisch W
    Hautarzt; 2003 Feb; 54(2):144-7. PubMed ID: 12590309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.
    Verma S; Quirt I; McCready D; Bak K; Charette M; Iscoe N
    Cancer; 2006 Apr; 106(7):1431-42. PubMed ID: 16511841
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant interferon therapy for melanoma.
    Hancock B; Wheatley K; Ives N; Gore M
    J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.